Protocol

Generation and differentiation of chemically derived hepatic progenitors from mouse primary hepatocytes

This protocol describes the generation of bipotent chemically derived hepatic progenitors (mCdHs) from mouse primary hepatocytes and their subsequent differentiation into either hepatic or cholangiocyte lineages. The reprogrammed mCdHs have a high proliferation capacity and express progenitor markers in long-term passages. Differentiated mCdHs show the characteristics of either hepatic or cholangiocyte genes. This protocol has potential application for regenerative medicine, including ex vivo gene therapy, disease modeling, drug screening, and personalized medicine.
Protocol

Generation and differentiation of chemically derived hepatic progenitors from mouse primary hepatocytes

Yohan Kim,1,2,4,5 Jaemin Jeong,1,2,* and Dongho Choi1,2,3,6,*

1Department of Surgery, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
2HY Indang Center of Regenerative Medicine and Stem Cell Research, Hanyang University, Seoul 04763, Republic of Korea
3Department of HY-KIST Bio-convergence, Hanyang University, Seoul 04763, Republic of Korea
4Present address: Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany
5Technical contact
6Lead contact
*Correspondence: jmj1103@gmail.com (J.J.), crane87@hanyang.ac.kr (D.C.)
https://doi.org/10.1016/j.xpro.2021.100840

SUMMARY

This protocol describes the generation of bipotent chemically derived hepatic progenitors (mCdHs) from mouse primary hepatocytes and their subsequent differentiation into either hepatic or cholangiocytes lineages. The reprogrammed mCdHs have a high proliferation capacity and express progenitor markers in long-term passages. Differentiated mCdHs show the characteristics of either hepatic or cholangiocytes genes. This protocol has potential application for regenerative medicine, including ex vivo gene therapy, disease modeling, drug screening, and personalized medicine.

For complete details on the use and execution of this protocol, please refer to Kim et al. (2021).

BEFORE YOU BEGIN

Before following these methods, prepare the materials referred in the key resources table.

Preparation of collagen-coated plates, reprogramming medium, and differentiation media

© Timing: 1 h to 1 day

Note: recipe tables are provided in the “materials and equipment” section.

1. Collagen-coated plates
   a. Dilute the collagen solution to 250 μg/mL in ice-cold 0.1% acetic acid.
   b. Add to the plate at a concentration of 10 μg/cm² and coat by spreading the collagen solution over the surface of the plate.
   c. Incubate for 1 h at 37°C or overnight (10–16 h) at 4°C.

2. Reprogramming medium (for primary hepatocytes in general)
   a. Add 1% fetal bovine serum (FBS), 1× insulin-transferrin-selenium, 0.1 μM dexamethasone, 10 mM nicotinamide, 50 μM β-mercaptoethanol, 20 ng/mL epidermal growth factor (EGF), 20 ng/mL hepatocyte growth factor (HGF), 4 μM A83-01, 3 μM CHIR99021, and 1% penicillin/streptomycin to DMEM/F-12 medium.
   b. Filter the medium through 0.45 μm cellulose acetate membranes. Store for up to 1 month at 4°C.

3. Hepatic differentiation medium (for re-differentiating general hepatocytes into hepatic lineage)
   a. Add 20 ng/mL oncostatin M and 10 μM dexamethasone to the reprogramming medium. Store for up to 1 month at 4°C.
4. Cholangiocyotic differentiation medium
   a. Add 10% FBS, 20 ng/mL HGF, and 1% penicillin/streptomycin to DMEM/F-12 medium. Store for up to 1 month at 4°C.

**Isolation of primary hepatocytes from mouse liver**

© Timing: 1–2 h

5. Prepare the perfusion solutions and medium
   a. Solution A: 0.19 g/L EDTA, 8 g/L NaCl, 0.4 g/L KCl, 0.078 g/L NaH$_2$PO$_4$·2H$_2$O, 0.151 g/L Na$_2$HPO$_4$·12H$_2$O, and 0.19 g/L HEPES in 1 L sterilized tertiary distilled water. Adjust the pH to 7.4. Store for up to 1 month at 4°C.
   b. Solution B: 0.3 g/L collagenase, 0.56 g/L CaCl$_2$, 8 g/L NaCl, 0.4 g/L KCl, 0.078 g/L NaH$_2$PO$_4$·2H$_2$O, 0.151 g/L Na$_2$HPO$_4$·12H$_2$O, and 0.19 g/L HEPES in 1 L sterilized tertiary distilled water. Adjust the pH to 7.4. Store for up to 1 month at 4°C.
   c. Hepatocyte culture medium: Add the Primary Hepatocyte Maintenance Supplements and 1% penicillin/streptomycin to 500 mL of Williams’ medium E.

6. The animal experiments are performed with permission of the IACUC (Institutional Animal Care and Use Committee). Anesthetize the 6–8 weeks-old mice (both male and female) with 2%–3% isoflurane and 4% O$_2$.

7. Make a U-shaped abdominal incision and find the portal vein.

8. Insert the 24G intravenous catheter into the portal vein and fasten the catheter in place with surgical thread.

9. Inject Solution A at a rate of 6 mL/min for 5 min at 37°C and cut the inferior vena cava (IVC).

10. Inject Solution B at a rate of 6 mL/min for 8 min at 37°C and extract the liver carefully.

11. Chop the liver with 50 mL of ice-cold Williams’ medium E without Primary Hepatocyte Maintenance Supplements on a petri dish and filter with a 100 μm cell strainer.

12. Wash the filtrate by centrifugation at 50 g for 5 min at 4°C. Discard the supernatant and resuspend the pellet by adding 50 mL of ice-cold Williams’ medium E. Repeat this step twice.

13. Discard the supernatant, add 50 mL of ice-cold 25% Percoll solution (diluted with DPBS), and centrifuge at 50 g for 5 min at 4°C without brake.

14. Discard the supernatant, add 5–10 mL of the hepatocyte culture medium with 1% penicillin/streptomycin to resuspend the pellet, and count the cell number. (The pellet consists of primary hepatocytes.)

15. Seed the cells in collagen-coated plates at 2,000 cells/cm$^2$ for further studies and incubate in a humidified atmosphere containing 5% CO$_2$ at 37°C (Figure 1A).

**Note:** Collagenase can be used interchangeably with other collagenases (type 1+2, type 4, type H) etc.
Figure 1. Generation of mouse chemically derived hepatic progenitors (mCdHs)
Morphological changes during the generation of mCdHs at day 0, 4, and 10 from adult mouse primary hepatocytes. Scale bars, 100 µm.

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies** | | |
| Goat anti-Albumin (1:100 dilution) | Abcam | Cat#ab19194, RRID:AB_777886 |
| Mouse anti-E-cadherin (1:100 dilution) | Abcam | Cat#ab76055, RRID:AB_1310159 |
| Rabbit anti-Epcam (1:100 dilution) | Abcam | Cat#ab32392, RRID:AB_732181 |
| Hoechst 33342 (1:10000 dilution) | Invitrogen | Cat#H3570 |
| Mouse anti-Cytokeratin 19 (1:100 dilution) | Santa Cruz Biotechnology | Cat#sc-376126, RRID:AB_10988034 |
| Rabbit anti-Sox9 (1:200 dilution) | Abcam | Cat#ab185966, RRID:AB_2728660 |
| Donkey anti-Goat, Alexa Fluor 488 (1:250 dilution) | Thermo Fisher Scientific | Cat#A-11055, RRID:AB_2534102 |
| Goat anti-Mouse, Alexa Fluor 488 (1:500 dilution) | Thermo Fisher Scientific | Cat#A-11001, RRID:AB_2534069 |
| Donkey anti-Rabbit, Alexa Fluor 594 (1:500 dilution) | Thermo Fisher Scientific | Cat#A-21207, RRID:AB_141637 |
| **Chemicals, peptides, and recombinant proteins** | | |
| A83-01 | Sigma-Aldrich | Cat#SML0788 |
| Acetic acid | Fisher Scientific | Cat#984303 |
| CaCl₂ | Sigma-Aldrich | Cat#C1016 |
| CHIR99021 | Sigma-Aldrich | Cat#SML1046 |
| Collagen Solution | STEMCELL Technologies | Cat#04902 |
| Collagen type I | Gibco | Cat#A10483-01 |
| Collagenase | Worthington Biochemical | Cat#KL002066 |
| Dexamethasone | Sigma-Aldrich | Cat#D8418 |
| DMEM/F-12 | Gibco | Cat#10565-018 |
| DMSO | Sigma-Aldrich | Cat#D8418 |
| DPBS | Welgene | Cat#LB001-02 |
| Ethylenediaminetetraacetic acid (EDTA) | Sigma-Aldrich | Cat#E8484 |
| Epidermal growth factor (EGF) | Peprotech | Cat#315-09 |
| Fetal bovine serum | Gibco | Cat#16000-044 |
| Gentamicin | Gibco | Cat#15710064 |
| HEPES | Sigma-Aldrich | Cat#H3375 |
| Hepatocyte growth factor (HGF) | PeproTech | Cat#100-39H |
| Insulin-transferrin-selenium | Gibco | Cat#S1500056 |
| Isoflurane | Piramal Critical Care | Cat#NDC66794-017 |
| KCl | Duchefa Biochemie | Cat#P0515 |
| Matrigel | Corning | Cat#356230 |
| Na₂HPO₄·12H₂O | Sigma-Aldrich | Cat#71649 |
| NaCl | Duchefa Biochemie | Cat#S0520 |
| NaH₂PO₄·2H₂O | Sigma-Aldrich | Cat#71505 |
| Nicotinamide | Sigma-Aldrich | Cat#N3376 |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Oncostatin M        | Prospec | Cat#cyt-231 |
| Penicillin/streptomycin | Gibco | Cat#15070-063 |
| Percoll (pH 8.9)    | Sigma-Aldrich | Cat#17-5445-02 |
| Primary Hepatocyte  | Gibco  | Cat#KM4000  |
| Primary Hepatocyte Maintenance Supplements | Gibco | Cat#12563029 |
| TrypLE Express Enzyme | Gibco | Cat#A12176-01 |
| TRIzol™ Reagent     | Thermo Scientific | Cat# 15596018 |
| Williams’ medium E  | Gibco  | Cat#CM4000  |
| β-mercaptoethanol   | Sigma-Aldrich | Cat#M3148  |

Critical commercial assays

| Protocol               | Source          | Cat#       |
|-----------------------|-----------------|------------|
| PAS stain kit         | Abcam           | Cat#ab150680 |
| qPCR PreMix           | Dyne Bio        | Cat#DYRT1202 |

Experimental models: Organisms/strains

| Mouse                  | Vendor         | Cat#       |
|------------------------|----------------|------------|
| C57BL/6N (6–8 weeks)   | Orient         | N/A        |

Oligonucleotides

| Primer | Forward | Reverse | Source   | Cat#       |
|--------|---------|---------|----------|------------|
| Aat    | (AATGGAAGAAGCCATCGAT) | (AAGACTGTAAACTGCTGCAG) | Macrogen | N/A        |
| Ae2    | (GACTCTTTTCCCTGTTGGA) | (AAGACTGTAACTGCTGCAG) | Macrogen | N/A        |
| Alb    | (GGCTACACGGGAACCACTGA) | (GCCGTGAAGGTTGTGGTG) | Macrogen | N/A        |
| Asgr1  | (CAGCTCTGTAGGACGGTTGA) | (GGGCCGTTCTGTTAGTTA) | Macrogen | N/A        |
| Agrp1  | (CTGTGGTTTCTGCGCTACCAC) | (GCACAGCAGACGCAATGAC) | Macrogen | N/A        |
| Cbp1a2 | (AGGGCTGAGGGAGGATTGG) | (TGTCCTGAGGCCATTTGAGAA) | Macrogen | N/A        |
| Cyp1a2 | (AGGGCTGCTGACGGGTTGTT) | (AGGTGTCCCTCGTTGACTA) | Macrogen | N/A        |
| Fxr    | (TGTGAGGGCTGCAAAGTTG) | (ACAGCATCTGCTGACTGAT) | Macrogen | N/A        |
| Gsh2   | (GTCTGCGTCCCTCTCGTCTC) | (TGACCTCTGCTCCTTG) | Macrogen | N/A        |
| Gapdh  | (CAGTCTGCGCCGCTTCTG) | (TGTCCTGAGGCCATTTGAGAA) | Macrogen | N/A        |
| Hnf4a  | (ATCGGAGGCAGGGGACAGAG) | (TCACCTCGCTCCTCTCCTG) | Macrogen | N/A        |
| Krt19  | (CTCGGAGGACATCCTGTTTG) | (GAGGACTCCCTCGGCTGACTGAT) | Macrogen | N/A        |
| Oct    | (TCCGGAAGCTCCTCCTTCG) | (GACTGCTGCGTGCTCGACTGAT) | Macrogen | N/A        |
| Trl    | (AGGTCTGCTGAGGGTACGAG) | (GACGGGCGCTCCTGCTGACTGAT) | Macrogen | N/A        |

Software and algorithms

| Software | Version | Link |
|----------|---------|------|
| GraphPad Prism 7 | Version 7.04 | https://www.leica-microsystems.com/products/confocal-microscopes/p/leica-tcs-sp5/ |

Other

| Item       | Source   | Cat#       |
|------------|----------|------------|
| 10 cm² plate | Coming | Cat#CLS430167 |
| 100 μm Cell strainer | Life Sciences | Cat#352360 |
| 6-well plate | Life Sciences | Cat#3516 |
MATERIALS AND EQUIPMENT

10 mL of collagen solution for collagen-coated plates

| Reagent               | Stock concentration | Final concentration | Amount  |
|-----------------------|----------------------|---------------------|---------|
| Collagen solution     | 3 mg/mL              | 250 μg/mL           | 830 μL  |
| Acetic acid           | 0.1% acetic acid     | N/A                 | 9.15 mL |
| Total                 |                      |                     | 10 mL   |

*Note: Store up to 1 week at 4°C*

500 mL of reprogramming medium

| Reagent                              | Stock concentration | Final concentration | Amount  |
|--------------------------------------|----------------------|---------------------|---------|
| DMEM/F-12                            | N/A                  | N/A                 | 480 mL  |
| FBS                                  | N/A                  | 1%                  | 5 mL    |
| Insulin-transferrin-selenium         | 100×                 | 1×                   | 5 mL    |
| Dexamethasone                        | 25.5 mM              | 0.1 μM              | 1.96 μL |
| Nicotinamide                         | 1 M                  | 10 mM               | 5 mL    |
| β-Mercaptoethanol                    | 140 mM               | 50 μM               | 178.57 μL |
| EGF                                  | 100 μg/mL            | 20 ng/mL            | 100 μL  |
| HGF                                  | 100 μg/mL            | 20 ng/mL            | 100 μL  |
| AS83-01                              | 10 mM                | 4 μM                | 200 μL  |
| CHIR99021                            | 10 mM                | 3 μM                | 150 μL  |
| Penicillin/streptomycin              | N/A                  | 1%                  | 5 mL    |
| Total                                |                      |                     | 500 mL  |

*Note: Store up to 1 month at 4°C*

50 mL of hepatic differentiation medium

| Reagent                              | Stock concentration | Final concentration | Amount  |
|--------------------------------------|----------------------|---------------------|---------|
| DMEM/F-12                            | N/A                  | N/A                 | 48 mL   |
| FBS                                  | N/A                  | 1%                  | 500 μL  |
| Insulin-transferrin-selenium         | 100×                 | 1×                   | 500 μL  |
| Dexamethasone                        | 25.5 mM              | 10 μM               | 19.6 μL |
| Nicotinamide                         | 1 M                  | 10 mM               | 500 μL  |
| β-Mercaptoethanol                    | 140 mM               | 50 μM               | 17.86 μL |
| EGF                                  | 100 μg/mL            | 20 ng/mL            | 10 μL   |
| HGF                                  | 100 μg/mL            | 20 ng/mL            | 10 μL   |
| AS83-01                              | 10 mM                | 4 μM                | 20 μL   |
| CHIR99021                            | 10 mM                | 3 μM                | 15 μL   |
| Penicillin/streptomycin              | N/A                  | 1%                  | 500 μL  |
| Oncostatin M                         | 100 μg/mL            | 20 ng/mL            | 10 μL   |
| Total                                |                      |                     | 50 mL   |
**Note:** Store up to 1 month at 4°C

### 50 mL of cholangiocyte differentiation medium

| Reagent                  | Stock concentration | Final concentration | Amount       |
|--------------------------|---------------------|---------------------|--------------|
| DMEM/F-12                | N/A                 | N/A                 | 44.5 mL      |
| FBS                      | N/A                 | 10%                 | 5 mL         |
| HGF                      | 100 μg/mL           | 20 ng/mL            | 10 µL        |
| Penicillin/streptomycin  | N/A                 | 1%                  | 500 µL       |
| **Total**                |                     |                     | **50 mL**    |

**Note:** Store up to 1 month at 4°C

---

### STEP-BY-STEP METHOD DETAILS

**Generation and maintenance of chemically derived hepatic progenitor cells**

**Timing:** 7–10 days

This step describes the generation of CdHs from mouse primary hepatocytes (mPHs). The protocol was adapted from the generation method for human CdHs (Kim et al., 2019).

1. Resuspend the mPHs in hepatocyte culture medium. Seed the freshly isolated mPHs on a collagen-coated plate at 2,000 cells/cm² and incubate overnight (10–16 h) with 5% CO₂ at 37°C.
2. Change hepatocyte culture medium to the reprogramming medium. Change the reprogramming medium every two days.
3. Culture the cells until they reach 75%–80% confluence (Figure 1).
4. Passage the cells at a ratio of 1:4
   a. Prewarm DPBS and TrypLE to room temperature (20°C–25°C). Prepare a collagen-coated plate, aspirate the collagen solution, wash the plate using DPBS, and add 7 mL of reprogramming medium (standard in 10 cm² plate).
   b. Aspirate the cultured medium and wash the cells with 2–3 mL DPBS.
   c. Add 2 mL TrypLE Express Enzyme and incubate for 5 min at 37°C.
   d. Detach the cells by gently pipetting and transfer to a 15 mL tube with 7 mL of reprogramming medium.
   e. Centrifuge at 200 g for 5 min at 4°C and aspirate the supernatant.
   f. Resuspend the pellet with 4 mL reprogramming medium and seed 1 mL of cells into a prepared 10 cm² plate.
   g. Incubate in a humidified atmosphere with 5% CO₂ at 37°C.
5. **Cryo-preservation**
   a. Count 1 × 10⁵ cells and add the reprogramming medium until the total volume is 900 µL.
   b. Add 100 µL DMSO and transfer each sample to a cryo-tube.

△ CRITICAL: Confluence of CdHs greater than 75%–80% led to a decrease in cell proliferation capacity, passaging efficiency and differentiation capacity. Passage CdHs before the cells are over-confluent (Figure 1C).
c. Place the cryo-tubes into a freezing container and store at –80°C deep freezer.

Note: For longer storage, transfer samples to liquid nitrogen after one day.

6. Thawing frozen CdHs
a. Prewarm the reprogramming medium and water bath. Prepare a collagen-coated plate, aspirate the collagen solution, wash the plate using DPBS, and add 7 mL of reprogramming medium (standard in 10 cm² plate).
b. Thaw the frozen CdHs in a 37°C water bath and slowly transfer into a 15 mL tube with pre-warmed 9 mL reprogramming medium.
c. Centrifuge at 200 g for 5 min at 4°C and aspirate the supernatant.
d. Resuspend the pellet in 1 mL reprogramming medium and seed the cells into a prepared 10 cm² collagen-coated plate.
e. Incubate in a humidified atmosphere with 5% CO₂ at 37°C.

Note: Usually you can get the cells with 80%–90% viability after thawing. To increase the cell viability, change the medium after 1 day of thawing.

Hepatic differentiation

© Timing: 9 days

This step describes the differentiation of CdHs into hepatocyte-like cells (CdH-Heps). The protocol was adapted from the hepatic differentiation method for human CdHs (Kim et al., 2019).

7. Prewarm the reprogramming medium and water bath set to 37°C. Prepare a collagen-coated plate, aspirate the collagen solution, wash the plate using DPBS, and add 1.5 mL of reprogramming medium (standard in 6-well plate).
8. Seed the CdHs on collagen-coated plates at 1,000 cells/cm² and incubate for 1 day in a humidified atmosphere with 5% CO₂ at 37°C.
9. After a 1-day incubation, change the reprogramming medium to the hepatic differentiation medium. The hepatic differentiation date begins at this point and is counted as day 0.
10. Change the medium every two days.
11. After 6 days, aspirate the culture medium and overlay the CdHs with the Matrigel mixture.
   a. Thaw the Matrigel in ice and prepare the ice-cold hepatic differentiation medium.
   b. Dilute the Matrigel with ice-cold hepatic differentiation medium at a 1:7 ratio on ice.
12. Incubate in a humidified atmosphere with 5% CO₂ at 37°C for 2 days (Figure 2).
Note: If differentiation is successfully completed, the differentiated cells will show the binuclear and bile canaliculi structures characteristic of hepatocytes.

Note: If you plan to conduct experiments such as measuring albumin secretion during the hepatic differentiation process, collect the conditioned medium—before changing the medium—on days 0, 2, 4, and 6. However, do not collect the medium on day 8 because it contains Matrigel.

13. Sampling for mRNA isolation.
   a. Gently add the ice-cold DMEM/F-12 (1 mL / 1,000 cells) to the cells and incubate for 5 min at room temperature.
   b. Gently aspirate the Matrigel mixture using a pipette.

△ CRITICAL: Be careful not to aspirate the cells with Matrigel mixture.

   c. Gently add the ice-cold DPBS (1 mL / 1,000 cells) to the cells and aspirate it.
   d. Add 1 mL of Tryp/LE and incubate for 3 min at 37°C.
   e. Detach the cells from the collagen-coated plate and transfer to a 15 mL tube with 9 mL of ice-cold DMEM/F-12.
   f. Centrifuge at 200 g for 5 min at 4°C and aspirate the supernatant.

Note: After centrifugation, if there is still an excessive quantity of Matrigel, add ice-cold DPBS, resuspend the pellet, and centrifuge again.

   g. Isolate the mRNA using TRIzol (Rio et al., 2010).

14. Sampling for immunocytochemistry
   a. Gently add 1 mL of ice-cold DPBS to the cells and incubate for 5 min at room temperature.
   b. Gently aspirate the Matrigel mixture using a pipette.

△ CRITICAL: Be careful not to aspirate the cells with Matrigel mixture. If the Matrigel mixture remains, repeat steps 14a and 14b.

   c. Fixation with 4% paraformaldehyde, methanol, etc., according to the experimenter’s immunocytochemistry protocol.
   d. Proceed to Immunocytochemistry.

Cholangiocyte differentiation

▯ Timing: 7 days

This step describes the differentiation of CdHs into cholangiocyte-like cells (CdH-Chols). The protocol was adapted from the cholangiocyte differentiation method for human CdHs (Kim et al., 2019).

15. Harvest the CdHs using Tryp/LE in the same manner as the passaging method.

16. Resuspend the pellet with cholangiocyte differentiation medium at a density of 1 \times 10^5 cells/well in a 6-well plate.

△ CRITICAL: Seeding with too high confluence makes it difficult for cells to form tubular-like structures.

17. Mix the cells with an equal volume of collagen type I (pH 7.0) on ice.

△ CRITICAL: If the mixture does not solidify, even after incubation for 30 min, the pH is not 7.0. Adjust collagen type I to pH 7.0, using NaOH or HCl, and mix with the cells.
18. Incubate for 30 min at 37°C.
19. Gently add 1 mL of the prewarmed cholangiocyte differentiation medium.
20. Incubate for 7 days in a humidified atmosphere with 5% CO2 at 37°C (Figure 3). Change the medium every two days using fresh cholangiocyte differentiation medium.

Note: If the differentiation process is done well, the cells form the tubular-like structure.

△ CRITICAL: Be careful not to aspirate the cells with the collagen mixture when changing the medium.

21. Sampling for mRNA isolation.
   a. Gently aspirate the cultured medium and wash with 1 mL DPBS.
   b. Aspirate the DPBS and add TRIzol or lysis buffer depending on the mRNA isolation methods.
22. Sampling for immunocytochemistry
   a. Gently aspirate the cultured medium and wash with 1 mL DPBS.
   b. Aspirate the DPBS gently.
   c. Fixation with 4% paraformaldehyde, methanol, etc., according to the experimenter’s immunocytochemistry protocol.
   d. Proceed to Immunocytochemistry.

EXPECTED OUTCOMES
Primary hepatocytes cannot proliferate and be passaged in vitro. If the reprogramming of primary hepatocytes to chemically derived hepatic progenitors proceeded well following this protocol, the cells will have acquired proliferative capacity (Figures 4A and 4B) and the ability to express progenitor/stem cell-specific markers (Figure 4C). Mouse CdHs (mCdHs) stably proliferate, can be cloned, and maintain the expression of progenitor/stem cell-specific markers even at passage 20 or more (Kim et al., 2021). These characteristics of mCdHs suggest that they can be used for ex vivo gene therapy and for bioartificial liver research that requires many cells (Strain and Neuberger, 2002).

Progenitors can differentiate into their organs of fate; specifically, hepatic progenitors can differentiate into hepatocytes and biliary epithelial cells (Dolle et al., 2010; Kim et al., 2019; Seaberg and van der Kooy, 2003). Therefore, if mCdHs reprogrammed through this protocol produced hepatic progenitors, they would differentiate into hepatocyte- and cholangiocyte-like cells according to the method described in this paper (Figures 2 and 3). mCdHs that have undergone hepatocyte differentiation show increased expression of hepatocyte-specific markers including Alb, Asgpr1, Hnf4a, Ttr, and Cytochrome P450 (Figure 5A). Also, they show the functional characteristics of mature

Figure 3. Cholangiocyte differentiation of mouse chemically derived hepatic progenitors (mCdHs)
Morphological changes during the cholangiocyte differentiation of mCdHs at day 0 (A) and 7 (B). Scale bars, 100 μm.

---

STAR Protocols 2, 100840, December 17, 2021
hepatocytes, including albumin secretion, cytochrome P450 activity, PAS staining, and ICG uptake (Kim et al., 2021). In addition, mCdHs can stably differentiate into hepatocytes even in long-term passages, and their gene expression profiles are similar to those of primary hepatocytes after differentiation (Kim et al., 2021). mCdH-Chols, which are differentiated into cholangiocyte lineages, show the expression of cholangiocytic-specific markers (Figure 5B). Bipotent differentiation capacity confirmed that mCdHs can differentiate into both hepatocytes and biliary epithelial cells in vivo after transplantation into a liver injury mouse model (Kim et al., 2019).

LIMITATIONS
In this paper we have described the most efficient reprogramming and differentiation methods that we have developed. However, there are many different methods for differentiating hepatocyte- and cholangiocyte-like cells from stem cells (Aurich et al., 2009; Ogawa et al., 2015; Sampaziotis et al., 2017; Sancho-Brus et al., 2011). In the case of cholangiocyte differentiation, 2D and 3D differentiation methods exist, and various small molecules and growth factors are used. Cholangiocytes display a tubular formation in vivo. Our protocol also uses the 3D culture method, but studies to improve differentiation efficiency by treatment of cells with additional growth factors and/or small molecules as proposed in other research papers are also needed to be explored.
TROUBLESHOOTING

Problem 1
At step 3, if the cells are continuously cultured beyond 75%–80% confluence, the cells will continue to divide, the cell size will tend to decrease, and finally the cells will detach from the plate (Figure 6). 

Potential solution
Passaging should be performed before the confluence reaches 80%–90%. If it will be a long period of time before the cells are needed, it is recommended to freeze the cells and thaw again when needed.

Problem 2
At steps 13 and 14, if the Matrigel mixture is aspirated without completely dissolving, the cells may be aspirated along with the Matrigel mixture.

Potential solution
When aspirating the Matrigel mixture or adding ice-cold DMEM/F-12 or DPBS, carefully aspirate and add along the wall of the plate. In addition, if the Matrigel mixture is not completely dissolved, dissolve the Matrigel mixture as much as possible by repeating the aspiration and addition of ice-cold DMEM/F-12 or DPBS steps.
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dongho Choi (crane87@hanyang.ac.kr).

Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and code availability
This study did not generate any unique data sets or code.

ACKNOWLEDGMENTS
This research was supported by grants from the National Research Foundation of Korea (NRF; 2021M3A9H3015390 to D.C.).

AUTHOR CONTRIBUTIONS
Y.K. conceived the study protocol and wrote the manuscript. J.J. and D.C. designed and supervised the study.

DECLARATION OF INTERESTS
Y.K., J.J., and D.C. filed a patent application based on this work.

REFERENCES
Aurich, H., Sgodda, M., Kaltwasser, P., Vetter, M., Weise, A., Liehr, T., Bruijl, M., Hengstler, J.G., Dollinger, M.M., Fleig, W.E., et al. (2009). Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58, 570–581.

Dolle, L., Best, J., Mei, J., Al Battah, F., Reynaert, H., van Grunsven, L.A., and Geerts, A. (2010). The quest for liver progenitor cells: a practical point of view. J. Hepatol. 52, 117–129.

Kim, Y., Hong, S.A., Yu, J., Eom, J., Jang, K., Yoon, S., Hong, D.H., Seo, D., Lee, S.N., Woo, J.S., et al. (2021). Adenine base editing and prime editing of chemically derived hepatic progenitors rescue genetic liver disease. Cell Stem Cell 28, 1614–1624.e5.

Kim, Y., Kang, K., Lee, S.B., Seo, D., Yoon, S., Kim, S.J., Jang, K., Jung, Y.K., Lee, K.G., Factor, V.M., et al. (2019). Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells. J. Hepatol. 70, 97–107.

Ogawa, M., Ogawa, S., Bear, C.E., Ahmadi, S., Chin, S., Li, B., Grompe, M., Keller, G., Kamath, B.M., and Ghanea, A. (2015). Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat. Biotechnol. 33, 853–861.

Sampaziotis, F., de Brito, M.C., Geti, I., Bertero, A., Hannan, N.R., and Vallier, L. (2017). Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte-like cells. Nat. Protoc. 12, 814–827.

Sancho-Bru, P., Roelant, P., Narain, N., Pauwelyn, K., Notelaers, T., Shimizu, T., Ott, M., and Verfaillie, C. (2011). Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells. J. Hepatol. 54, 98–107.

Seaberg, R.M., and van der Kooy, D. (2003). Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci. 26, 125–131.

Strain, A.J., and Neuberger, J.M. (2002). A bioartificial liver–state of the art. Science 295, 1005–1009.

Figure 6. Results of over-confluence of mCdHs
Morphological changes in cells during culture at over 75%–80% confluence for 60 days.
(A) Mouse chemically derived hepatic progenitor (mCdHs) after reaching the appropriate confluence for passaging.
(B) Dense growth of mCdHs in the middle of a colony, accompanied by decrease in cell size.
(C) Detachment of cells from the collagen-coated plate. Scale bars, 100 μm.